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The Ubiquitin-Proteasome Pathway (UPP), which is critical for normal function in the
nervous system and is implicated in various neurological diseases, requires the small
modifier protein ubiquitin to accomplish its duty of selectively degrading short-lived,
abnormal or misfolded proteins. Over the past decade, a large class of proteases
collectively known as deubiquitinating enzymes (DUBs) has increasingly gained attention
in all manners related to ubiquitin. By cleaving ubiquitin from another protein, DUBs
ensure that the UPP functions properly. DUBs accomplish this task by processing newly
translated ubiquitin so that it can be used for conjugation to substrate proteins, by
regulating the “where, when, and why” of UPP substrate ubiquitination and subsequent
degradation, and by recycling ubiquitin for re-use by the UPP. Because of the reliance of the
UPP on DUB activities, it is not surprising that these proteases play important roles in the
normal activities of the nervous system and in neurodegenerative diseases. In this review,
we summarize recent advances in understanding the functions of DUBs in the nervous
system. We focus on their role in the UPP, and make the argument that understanding
the UPP from the perspective of DUBs can yield new insight into diseases that result
from anomalous intra-cellular processes or inter-cellular networks. Lastly, we discuss the
relevance of DUBs as therapeutic options for disorders of the nervous system.
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INTRODUCTION
The Ubiquitin Proteasome Pathway (UPP) is responsible for
degrading the majority of proteins in eukaryotic cells. The
UPP is important to all steps and processes of the nervous
system, including cell fate specification, differentiation, migra-
tion, networking, and maturation, and is critical in maintaining
neuronal homeostasis during ageing. As post-mitotic cells, neu-
rons cannot disperse toxic or misfolded proteins through cell
division, but must instead continuously rid themselves of cel-
lular components whose accumulation could be detrimental.
The importance of the UPP to the ageing nervous system is
exemplified by neurodegenerative disorders such as Alzheimer’s,
Parkinson’s and other diseases, where pathological hallmarks
are the accumulation and aggregation of proteins with toxic
properties.
Degradation of proteins by the UPP is a highly selective
process. In order for proteins to be degraded by the protea-
some, they require a “tag” to identify them as substrates. This
“tagging” task is accomplished through the post-translational
modification of substrates with the small modifier protein ubiq-
uitin (Ub). Ubiquitination involves the covalent attachment of
Ub via an isopeptide bond to a lysine residue of target proteins
through the coordinated action of a Ub activating enzyme (E1;
two such enzymes are known in mammals), a Ub conjugating
enzyme (E2; ∼50–75 in mammals), and a Ub ligase (E3; >500
in mammals) (Figure 1).
Ub can be added onto a protein as a monomer or as a poly-
Ub chain. Poly-Ub can take on different topographies due to the
presence of seven lysine residues on Ub itself, creating chains of
different linkage types: K6, K11, K27, K29, K33, K48, and K63.
Different types of chains signal different outcomes. In the case
of UPP, K48-linked chains consisting of at least four Ub most
commonly identify a protein as a proteasome substrate (Thrower
et al., 2000; Komander and Rape, 2012; Heride et al., 2014). K11
chains have also been implicated in protein degradation during
mitosis (Jin et al., 2008), although it is not clear how widely these
chains are utilized by the UPP in other cellular processes.
The proteasome is able to bind both K63- and K48-
linked chains in reconstituted systems in vitro (Kim et al.,
2007; Peth et al., 2010). However, in mammalian cells there
appears to be selectivity for K48-linked poly-Ub by the pro-
teasome (Nathan et al., 2013). K63-linked poly-Ub chains
are bound by proteins involved in the Endosomal Sorting
Complex Required for Transport (ESCRT) pathway, which
do not function directly with the proteasome. Binding of
K63-linked poly-Ub by ESCRT proteins seemingly precludes
the proteasomal degradation of proteins modified with this
type of chain (Nathan et al., 2013). Additional specificity in
poly-Ub recognition is provided by a family of proteasome-
associated proteins, including the Rad23 orthologs hHR23A and
hHR23B that selectively bind K48-linked chains (Nathan et al.,
2013).
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FIGURE 1 | Summary of the UPP. Through the coordinated action of
E1/E2/E3, Ub is conjugated to a substrate destined for proteasomal
degradation. Ub-binding proteins that are part of the 19S or that associate
with it reversibly (not depicted) bind poly-Ub on the substrate, which is
subsequently deubiquitinated, unfolded and degraded. Poly-Ub is then
processed into mono-Ub which re-enters the cycle.
The 26S proteasome is a macromolecular structure composed
of a catalytic 20S subunit and one or two 19S regulatory subunits.
Ubiquitinated substrates are recognized by and bind to the 19S
particle. This process is accomplished in part by the integral 19S
receptors S5a and Adrm1. Ubiquitinated proteins that are bound
by the 19S proteasome are deubiquitinated and unfolded. The
unfolded proteins can then pass through the hollow, cylindrical
core of the 20S particle, where they are enzymatically degraded.
Erroneous ubiquitination of a protein could send it to the
proteasome prematurely, or could target it for the wrong path-
way (e.g., autophagy rather than the UPP), leading to unintended
consequences for cells. Specificity for which proteins are ubiq-
uitinated and the type of Ub linkage formed rests in large part
with the E2/E3 pair that performs the ubiquitination process
(Komander and Rape, 2012; Heride et al., 2014). An additional
level of control is provided by enzymes known as deubiquitinases
(DUBs), which reverse the isopeptide bond and thus help to con-
trol the status of protein ubiquitination. An increasing number of
reports is being published on the role of DUBs in nearly all cellular
pathways, tissues and organs, in normal homeostasis and in vari-
ous diseases, including disorders of the nervous system (Todi and
Paulson, 2011; Clague et al., 2013).
The nearly 95 DUBs that are encoded by the human genome
are subdivided into five categories based on homology at the
catalytic domain. The Ubiquitin C-terminal Hydrolases (UCH),
Ubiquitin Specific Proteases (USP), Machado-Joseph Disease
Proteases (MJD), and Otubain (OTU) Proteases are cysteine pro-
teases, while JAB1/MPN/Mov34 Metallo-enzyme (JAMM) pro-
teases are zinc-dependent metallo-proteases (Figure 2). DUBs
maintain the cellular pool of mono-Ub available for conjugation
by processing Ub precursors; they replenish mono-Ub by cleaving
poly-Ub chains and recycling Ub; they can fully deubiquitinate
substrates and reverse their outcome; or they can edit poly-Ub
chains on substrates to help direct them toward a specific pathway
(Figure 3). Although at the most basic level catalytically active
DUBs perform a similar function—disassembly of Ub-protein
bonds—in vitro and in vivo studies have collected evidence that
these proteases have various non-redundant roles (Clague et al.,
2013). Distinct roles stem in part from differences in the structure
of the catalytic domains of DUBs and in part from interaction
domains and subcellular localization signals encoded in their
amino acid sequences.
Three DUBs associate directly with the proteasome: PSMD14,
USP14, and UCHL5. PSMD14 is a stoichiometric component of
the 19S regulatory subunit, whereas USP14 and UCHL5 asso-
ciate transiently with it during protein degradation. Several other
DUBs function in conjunction with the UPP at steps that precede
the proteasome (e.g., during substrate ubiquitination) or follow-
ing substrate binding to the 19S (e.g., during ubiquitin chain
disassembly and ubiquitin recycling; Figure 4). The following sec-
tions provide details on UPP-related DUBs in the nervous system,
with examples from each sub-class of this family. The exception
are OTU proteases, for which there are fewmechanistic data relat-
ing them to the UPP in the nervous system. Information that has
been reported so far on OTUs is included in Table 1, which is a
comprehensive list of DUBs implicated in the nervous system, and
also includes proteases that do not necessarily function through
the UPP.
UPP-RELATED DUBs IN THE NERVOUS SYSTEM
PROTEASOME-ASSOCIATED DUBs
PSMD14
This metallo-protease belongs to the JAMM sub-family of DUBs.
It is also known as POH1. PSMD14 is a constitutive subunit of
the proteasome, a member of the 19S regulatory complex, where
it neighbors the ubiquitin receptor Adrm1 (Beck et al., 2012).
Its reported role is to deubiquitinate proteins at the proteasome
before they are degraded. By removing Ub chains en bloc from
substrates, PSMD14 plays an important role in facilitating protein
degradation, as well as in Ub recycling. Once poly-Ub is removed
from substrates by PSMD14 it is disassembled by other DUBs, for
example USP5 (Clague et al., 2013; Liu and Jacobson, 2013).
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FIGURE 2 | Mammalian DUBs. Mammalian DUBs categorized by similarities at the protease domain. Highlighted are DUBs involved in the nervous system.
With the exception of JAMM proteases, which are zinc-dependent metallo-proteases, the rest are cysteine proteases.
FIGURE 3 | Roles of DUBs in Ub homeostasis. Diagrammatic summary of
the various functions of DUBs in Ub homeostasis. Newly produced Ub is
C-terminally fused to other proteins, such as other Ub molecules, and must
be cleaved by DUBs in order for its terminal glycine residue to be exposed for
isopeptide bond formation. Once conjugated to a substrate protein, poly-Ub
chains can be edited, or can be completely removed. Poly-Ub chains that are
unanchored are processed into single Ub and re-enter the Ub conjugation
cycle.
PSMD14 and its role at the proteasome were uncovered
through studies in yeast that examined how deubiquitination
and degradation of a substrate are coupled. In yeast, PSMD14 is
known as Rpn11. Through the use of an unfolded, ubiquitinated
model substrate, it was shown that deubiquitination occurs after
a protein is bound by the proteasome. Mutating Ub so that it can
no longer be cleaved by DUBs leads to a significant reduction
of substrate degradation. Other studies showed that substrate
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Table 1 | DUBs in the nervous system.
UCH
UCHL1 Lack of UCHL1 causes gracile axonal dystrophy in mice. Mutations have been linked
to PD and other diseases. An N-terminal truncation of this DUB may prevent PD-like
damage in cultured cells, potentially by reducing oxidative stress. Primary function of
this DUB appears to be mono-Ub maintenance.
Larsen et al., 1998; Setsuie and Wada,
2007; Bilguvar et al., 2013; Kim et al.,
2014
UCHL3 Mutations in mice cause learning and working memory deficits. Also observed are
muscular and retinal degeneration, potentially due to oxidative stress.
Kurihara et al., 2000; Wood et al.,
2005; Sano et al., 2006
UCHL5/UCH37 Reversibly associates with the 19S component of the proteasome and
deubiquitinates proteasome substrates. Uchl5 knockout mice die during development
due to brain malformations. In non-neural tissue, may regulate TGF-β signaling.
Wicks et al., 2005; Al-Shami et al.,
2010; Clague et al., 2013
USP
USP2 Involved in regulating the sensitivity to light of the circadian system in mice by
deubiquitinating the transcription factor BMAL1. This DUB is upregulated in
high-grade gliomas. Pan-neuronal knockdown in Drosophila leads to reduced
locomotion and earlier adult lethality.
Scoma et al., 2011; Tsou et al., 2012;
Tao et al., 2013
USP5 Co-purifies with synaptic 26S proteasome from rat cortex. Recycles mono-Ub by
hydrolyzing unanchored ubiquitin chains. Pan-neuronal knockdown in Drosophila
causes reduced motility and earlier adult death.
Reyes-Turcu et al., 2009; Tai et al.,
2010; Tsou et al., 2012
USP7 Largely functions by preventing the proteasomal degradation of proteins, including
p53 and REST. Brain-specific knockout causes brain malformation and neonatal
lethality in mice, due at least in part to p53-dependent mechanisms.
Li et al., 2002; Huang et al., 2011; Kon
et al., 2011
USP8 Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
USP9X Involved in neuronal fate specification and NMJ function. Evidenced to regulate the
degradation of the neurodegenerative disease protein α-synuclein by deubiquitinating
it. May function outside of the UPP.
Huang et al., 1995; Fischer and
Overstreet, 2002; Rott et al., 2011
USP13 Co-purifies with synaptic 26S proteasome from rat cortex. Tai et al., 2010
USP14 Associates reversibly with the 19S proteasome and deubiquitinates proteasome
substrates. Primary role in the nervous system appears to be maintenance of
mono-Ub for reuse. May deubiquitinate specific substrates, including the
neurodegenerative proteins tau and ataxin-3 to suppress their degradation, and the
Wnt signaling regulator Dishevelled to regulate its interaction with partners.
Mutations in mice cause ataxia and lead to abnormal NMJ structure and function,
which is suppressed by reintroducing mono-Ub.
Wilson et al., 2002; Chen et al., 2009,
2011; Lee et al., 2010a; Jung et al.,
2013
USP18 Knockouts in mice cause tremors, loss of balance, convulsions, and premature death.
Anomalies appear to be related to the Ub-like protein ISG15, which USP18 can
de-conjugate.
Ritchie et al., 2002; Knobeloch et al.,
2005
USP22 Its Drosophila ortholog regulates axonal projection of photoreceptor cells. Yi and Ehlers, 2007
USP24 May be involved in PD susceptibility, according to gene linkage analysis. Li et al., 2006
USP25 Overexpressed in human Down syndrome brains. Evidenced to prevent the
proteasomal turnover of the AD-related protein APP.
Valero et al., 1999; Blount et al., 2012
USP30 Opposes parkin-mediated mitophagy by deubiquitinating mitochondria in mammalian
cells. Knockdown in Drosophila dopaminergic neurons suppresses PD-like
degeneration.
Bingol et al., 2014
USP33 Regulates axonal pathfinding during development by regulating the stability or
surface exposure of the axonal guidance receptor Roundabout.
Yuasa-Kawada et al., 2009
USP34 Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
(Continued)
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Table 1 | Continued
USP36 Pan-neuronal knockdown in Drosophila leads to reduced locomotion and earlier adult
death.
Tsou et al., 2012
USP39 Glial-restricted knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
USP40 May be involved in PD susceptibility, according to gene linkage analysis. Li et al., 2006
USP46 Mutations in this DUB in mice cause anomalies in circadian rhythm and behavioral
abnormalities during stress. In C. elegans, this DUB regulates lysosomal degradation
of glutamate receptors.
Tomida et al., 2009; Kowalski et al.,
2011; Kowalski and Juo, 2012
USP47 Pan-neuronal knockdown in Drosophila leads to reduced locomotion and early adult
death.
Tsou et al., 2012
USP54 Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
MJD
Ataxin-3 Mutations in it cause the neurodegenerative disease SCA3. Evidenced to cooperate
with several E3 Ub ligases. May assist with the degradation of various UPP
substrates. Suppresses polyglutamine-dependent degeneration in Drosophila.
Costa Mdo and Paulson, 2012; Tsou
et al., 2013
OTU
OTUB1 Found in Lewy bodies in post-mortem PD brains. Xia et al., 2008
OTUD4 Mutations in this DUB and the E3 Ub ligase RNF216 have been linked to syndromic
hypogonadotropic hypogonadism, ataxia, and dementia in humans. Knockdown in
zebrafish causes anomalous development of the eye, optic tectum, and cerebellum.
Margolin et al., 2013
Otulin/Gumby Mutations in the murine version of this DUB, which cleaves linear Ub chains, cause
anomalies in angiogenesis, neuronal, and craniofacial development as a result of
perturbed Wnt signaling.
Rivkin et al., 2013
JAMM
PSMD14 Stoichiometric subunit of the 19S proteasome. Deubiquitinates substrates at the
proteasome. Pan-neuronal knockdown in Drosophila leads to lethality during
development.
Verma et al., 2002; Yao and Cohen,
2002; Clague et al., 2013
EIF3H Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
AMSH Knockout mice die young. Neuronal loss is observed in the cerebral cortex and the
hippocampus.
Ishii et al., 2001; Suzuki et al., 2011
deubiquitination at the proteasome is insensitive to molecules
that block cysteine proteases, whereas a zinc chelator blocks deu-
biquitination, suggesting a metallo-enzyme. Mutations in Rpn11
stabilize UPP substrates and are lethal in yeast. These and other
studies pointed to Rpn11 as the DUB functioning at the pro-
teasome, bridging substrate deubiquitination and degradation
(Verma et al., 2002; Yao and Cohen, 2002).
Work conducted in mammalian cell culture implicated
PSMD14 in maintaining the post-mitotic status of neurons.
RNAi-mediated knockdown of PSMD14 in mouse midbrain and
cortical cultures leads to de novo synthesis of DNA and an increase
in apoptosis (Staropoli and Abeliovich, 2005). The mechanism
behind these observations is unclear, but these data suggest a
critical role for UPP in preventing neurons from re-entering
mitosis. Perhaps disturbance of the UPP (from the perspective of
PSMD14) triggers a general cellular stress response that ultimately
leads to neuronal death. Alternatively, the UPP could be involved
in the continuous turnover of specific factors that induce mitotic
re-entry. Highlighting the importance of PSMD14 to the nervous
system, RNAi-mediated knockdown of its ortholog in neurons in
Drosophila causes larval lethality (Tsou et al., 2012).
PSMD14 is one of very few DUBs with a specific function, in
this case, the removal of poly-Ub chains in a single swoop from
substrates at the proteasome. As it will become clear through the
remainder of this review, it is difficult to categorize most DUBs as
operating in only one step, or acting on only one substrate, path-
way, tissue, or organ. Perhaps PSMD14 is an exception because of
its continuous presence at the 19S subunit, where it is precluded
from interacting with other potential partners. Most other DUBs
do not appear to reside in a single constitutive molecular com-
plex and can thus conduct different functions depending on their
interactions.
UCHL5
This DUB is a member of the UCH sub-family and is also known
as UCH37. Unlike PSMD14, UCHL5 is not a constitutive subunit
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of the proteasome but associates with it by binding to the Ub
receptor Adrm1 on the 19S subunit (Lee et al., 2010a,b). The
proposed role for this DUB at the proteasome is one of poly-Ub
chain trimming by hydrolyzing Ub chains at their distal end and
releasing mono-Ub for re-utilization (Yao et al., 2006). UCHL5
deubiquitinating activity has been shown to increase once it is
bound to the proteasome (Qiu et al., 2006; Yao et al., 2006). Based
on more recent work, UCHL5 stimulates the activity of the pro-
teasome by regulating ATP hydrolysis and 20S gate opening (Peth
et al., 2009, 2013a,b).
Studies in a Uchl5-null mouse line showed that this protease
is important for brain development. Uchl5 knockout embryos
have malformations in various brain areas, including the telen-
cephalon, mesencephalon, and metencephalon (Al-Shami et al.,
2010). The reasons for these specific anomalies are not known.
Other proteasome-associated DUBs, such as USP14, which is dis-
cussed next and which also processes chains to yield mono-Ub,
appear unable to compensate for the loss of UCHL5, indicating a
non-redundant role for this DUB in the brain.
USP14
USP14 belongs to the USP sub-family of DUBs. It reversibly
associates with the 19S proteasome, where it is responsible for
trimming Ub chains on substrates that are destined for degrada-
tion and thus recycling mono-Ub. The catalytic activity of USP14
is enhanced by its binding to the proteasome several hundred-fold
(Lee et al., 2010a,b), suggesting that this DUB needs the pro-
teasome in order to conduct functions that require its protease
activity.
Depletion of USP14 alone enhances proteasome activity,
whereas co-depletion with UCHL5 inhibits the proteasome
(Koulich et al., 2008), indicating some cross-dependence for these
DUBs during protein degradation. Critical information on the
function of USP14 has come from yeast studies, where deple-
tion of Ub leads to an upregulation of its ortholog, Ubp6, which
restores Ub balance (Hanna et al., 2006). Not all functions of
USP14 at the proteasome depend on its catalytic activity: bind-
ing of USP14 to poly-Ub chains and unfolded peptides results in
opening of the gates of the 20S proteasome and stimulation of
the ATPase activity of the proteasome (Peth et al., 2009, 2013a,b).
Collectively, these findings implicated USP14 with keeping pro-
teasomal activity under check.
A role for USP14 in the nervous system was first demonstrated
by the identification of a recessive mutation in the Usp14 gene,
which causes ataxia in the axJ mouse line. Homozygous axJ mice
suffer from progressive motor impairment including ataxia and
tremor, reduced body and brain mass, paralysis and death by 2
months of age. The axJ mutation results from the insertion of an
intracisternal-A particle into intron 5 of Usp14, leading to ∼95%
lower levels of USP14 protein in the brain of homozygous mice
(Wilson et al., 2002; Anderson et al., 2005). In contrast to many
mouse models of neurodegenerative diseases, axJ mice do not
show neuronal loss or abnormal protein accumulation (Wilson
et al., 2002). Instead, axJ mice have reduced mono-Ub levels, par-
ticularly in synaptosomal fractions (Anderson et al., 2005; Chen
et al., 2009, 2011). The introduction of Ub in neurons in an axJ
background largely suppresses the phenotype (Chen et al., 2011),
indicating that a primary role of USP14 in the central nervous
system is Ub homeostasis.
USP14 is critically important at the neuromuscular junction
(NMJ). Recordings in axJ mice reveal defective release of the
neurotransmitter acetylcholine (ACh) at the NMJ, and loss of
USP14 leads to developmental anomalies at the pre- and post-
synaptic terminals of the NMJ (Chen et al., 2009). The NMJs of
axJ mice are swollen and poorly arborized, with aberrant nerve
terminals and an immature morphology of ACh receptor clusters.
These changes correlate with loss of mono-Ub, and are corrected
by exogenous expression of Ub in neurons (Chen et al., 2009,
2011).
The ataxia phenotype in the axJ mice suggests that the
cerebellum is negatively affected by nearly absent USP14. A
potential role for this DUB in regulating the activity of cere-
bellar Purkinje cells has been reported. In axJ mice, Purkinje
cells have increased cell surface expression of GABAA Receptors
(GABAAR) in extrasynaptic regions, with a concomitant increase
in inhibitory GABAergic currents that effectively reduces cerebel-
lar output (Lappe-Siefke et al., 2009). GABAAR is ubiquitinated
in cells and USP14, which interacts directly with this receptor,
may deubiquitinate it (Lappe-Siefke et al., 2009). Generally speak-
ing, mono-ubiquitination controls recycling of various receptors
to and from the cell membrane, including GABAAR (Saliba et al.,
2007). Consequently, USP14 deficiency may cause ataxia in the
axJ mice in part by perturbing the turnover and/or cell surface
distribution of GABAAR. Still, since it is not clear that USP14
directly deubiquitinates GABAAR, it is also worth considering
that this DUB may regulate the receptor indirectly. After all,
USP14 is a sluggish protease outside of the proteasomal context,
leading one to wonder whether it can deubiquitinate GABAAR in
the absence of factors that enhance its catalytic activity.
Because of the early lethality phenotype in the axJ mice, it has
been difficult to investigate whether USP14 is important in adults.
Recently, another mutation in Usp14 was identified (Marshall
et al., 2013). This mutation, nmf375, leads to ∼95% reduction
in USP14 protein levels when homozygous, similar to the reduc-
tion observed in axJ mice. However, unlike axJ homozygous
mice, ones carrying two copies of nmf375 do not present with
phenotypes early in life. Deterioration of motor performance is
observed around 12 months of age (axJ mice die by 2 months)
and is associated with mono-Ub depletion (Marshall et al., 2013).
These data indicate that USP14 plays an important role not only
for NMJ development, but also for its maintenance. They also
highlight the importance of geneticmodifiers: mutations that lead
to similar reduction in USP14 protein levels in different genetic
backgrounds have markedly different phenotypic onset and pro-
gression. Placing the nmf375 into the same genetic background as
the axJ leads to a dramatically earlier phenotype, evenmore severe
than axJ (Marshall et al., 2013). Perhaps future genetic analyses
will identify factors that modulate the phenotype caused by this
UPP-related DUB. Could these modifiers be other DUBs related
to the UPP, or are they E3 ligases that counteract USP14 function?
Studies from yeast, mammalian cell culture and mice together
indicate that USP14 plays an important role in recycling mono-
Ub by functioning at the proteasome. Other studies have
presented the possibility that this DUB has specific substrates,
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potentially outside of the UPP. As described later, there is even
evidence from cell culture that USP14 prevents the degradation of
some ubiquitinated substrates at the proteasome, adding further
complexity to the functions of this protease (see the Section on
“The use of DUBs for therapeutic purposes”). Future work may
find distinct binding partners of USP14 that depend on cell type,
the state of neuronal activity, and on sub-cellular localization. In
turn, these partners may dictate the precise function of USP14 as
a DUB, or even as a scaffolding protein.
DUBs THAT FUNCTION IN CONJUNCTION WITH THE UPP
UCHL1
The first reported DUB with a neuronal function, UCHL1 is a
member of the UCH sub-family of DUBs. The catalytic area of
UCHL1 has a loop positioned over the active site, which limits the
size of Ub adducts that can be processed by it to small peptides
(Johnston et al., 1999; Das et al., 2006). Based on in vitro bio-
chemical reactions, structural data and observations from animal
studies, UCHL1 is proposed to function largely by maintaining
a stable pool of mono-Ub for use in ubiquitination reactions
(Clague et al., 2013). Newly translated Ub contains amino acids
following the terminal glycine residue that is used for isopeptide
bond formation. UCHL1 can cleave off these additional amino
acids in order to expose the final glycine of Ub for conjugation.
UCHL1 can also help maintain mono-Ub by reversing accidental
modifications that can form during Ub activation (Larsen et al.,
1998).
UCHL1 was first described in Aplysia, where its ortholog is
known as Ap-UCH (Hegde et al., 1997). This protease was found
to have a role in synaptic plasticity because it was one of the
genes that was markedly upregulated in sensory neurons follow-
ing LTF (long-term facilitation) and LTD (long-term depression).
Inhibition of Ap-UCH induction or blockage of its function
inhibits synaptic plasticity (Chain et al., 1995; Hegde et al., 1997;
Fioravante et al., 2008).
UCHL1 is among the most abundant proteins in the brain, by
some estimates reaching 1–2% (Jackson and Thompson, 1981;
Doran et al., 1983; Wilkinson et al., 1992). Similar to Ap-UCH
in Aplysia, mammalian UCHL1 is linked to synaptic function.
Studies of mouse knockouts of the Uchl1 gene indicate that this
DUB is important for the structure and function of the NMJ.
Uchl1 knockout mice develop normally, but die prematurely after
a period of spasticity and paralysis. At the level of the NMJ, Uchl1
knockouts show a significant decrease in the release of ACh from
the synaptic terminal (Chen et al., 2010), which could be due to
perturbed Ub-dependent pathways as a result of decreased Ub
recycling. This reduction in content release is accompanied by
hindered synaptic plasticity, nerve terminal retraction and axonal
degeneration (Chen et al., 2010). Supportive evidence for a role
for UCHL1 at the synapse also comes from the gad (gracile axonal
dystrophy) mouse line, which has an intragenic Uchl1 deletion
(Saigoh et al., 1999). Similar to the Uchl1 knockout mice, ones
homozygous for gad present with a dying-back type of axonal
degeneration. Lastly, studies in rat hippocampal slices also col-
lected evidence that UCHL1 is important for synaptic plasticity
by maintaining mono-Ub. Increased UCHL1 activity leads to
higher levels of mono-Ub, whereas pharmacological inhibition of
this DUB has the opposite effect and is associated with anoma-
lous synaptic spine structure (Cartier et al., 2009). Importantly,
anomalies at the synaptic level during UCHL1 inhibition are
rescued by the introduction of mono-Ub (Cartier et al., 2009).
Together, these data indicate that a primary role for UCHL1 in
the nervous system is to maintain mono-Ub available for utiliza-
tion during inter-cellular communication. This pool of mono-Ub
could be utilized by the UPP as well as other types of cellu-
lar pathways and processes, such as gene transcription, receptor
internalization, autophagy, etc.
UCHL1 is important to the ageing nervous system, as high-
lighted by the connection of this DUB to age-related diseases,
including Alzheimer’s (AD) and Parkinson’s (PD). Based on pro-
teomic studies, UCHL1 is a major target of oxidative damage
in AD and PD post-mortem human brains (Choi et al., 2004).
UCHL1 protein levels are reduced in the hippocampus of a
transgenic mouse model of AD that has learning deficits and
impaired LTF (Gong et al., 2006). Similarly, soluble UCHL1 lev-
els are decreased in post-mortem AD brains, potentially due to its
sequestration in neurofibrillary tangles (Setsuie andWada, 2007).
Introduction of UCHL1 in transgenic AD mice and in cultured
cells alleviates cognitive defects and restores synaptic plasticity in
a manner dependent on its catalytic activity (Gong et al., 2006).
These and other findings support previously mentioned data
that UCHL1 is important at synapses, and suggest that increased
UCHL1 activity could counteract certain symptoms in AD.
Other work proposes that UCHL1 has specific substrates and
may increase UPP-dependent degradation of the β-site amyloid
precursor protein (APP) cleaving enzyme 1 (BACE1). BACE1
sequentially cleaves APP into amyloid ß (Aß) protein, which
is a major component of neuritic plaques, a hallmark of AD.
Pharmacological inhibition of UCHL1 in cultured cells leads to an
increase in BACE1 protein levels, whereas an increase in UCHL1
levels has the opposite effect and is associated with reduced levels
of Aß protein. Studies in cultured cells are supported by investi-
gations in gad mice. Measuring hippocampal levels of BACE1 by
western blotting shows an increase in its protein levels in gadmice
compared to wild type counterparts (Zhang et al., 2012).Whether
UCHL1, with its physically constrained catalytic site, can deubiq-
uitinate BACE1 and how this would accelerate its degradation is
presently unclear. Another possibility is that reduced mono-Ub
levels as a result of UCHL1 perturbation inhibits the UPP more
generally, which in turn impacts BACE1 stability.
In relation to PD, a missense mutation in UCHL1 (I93M)
was described in 1998 as the cause of dominantly-inherited PD
in a family (Leroy et al., 1998). In in vitro reconstituted assays,
UCHL1I93M was found to have reduced DUB activity (Nishikawa
et al., 2003), thus it was initially hypothesized that PD could
be due to partial loss of UCHL1 activity. However, mice lacking
UCHL1 do not develop neurodegenerative hallmarks of PD, such
as loss of dopaminergic neurons, indicating that PD in the I93M
family might not be due to reduced UCHL1 activity, but could
result from a gain-of-function. To examine this latter possibil-
ity, transgenic mice were generated expressingUCHL1I93M. These
mice show loss of nigral dopaminergic neurons, as is characteris-
tically seen in PD, and develop Ub- and UCHL1-positive inclu-
sions, although not Lewy Bodies, which are the histopathological
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hallmark of PD (Setsuie and Wada, 2007; Setsuie et al., 2007; Tan
and Skipper, 2007). According to these results, UCHL1I93M could
cause neurodegeneration through a gain-of-function mecha-
nism. The molecular process through which this mutation would
impact UCHL1 cellular function, localization or other properties
is unclear.
Another report that linked UCHL1 to PD presented evidence
that the DUB activity of a farnesylated, membrane-bound form
of this protease rescues the PD protein, α-synuclein, from lyso-
somal degradation (Liu et al., 2009). α-synuclein is implicated
in the buildup of aggregated structures in patient brains, and
this buildup is believed to be one cause of death of dopamin-
ergic neurons in PD (Kruger et al., 1998; Athanassiadou et al.,
1999; Tan and Skipper, 2007). If it is confirmed in vivo that
farnesylated UCHL1 has a significant role in the turnover of
α-synuclein, it would suggest this DUB as a potential therapeu-
tic target for PD. Severing UCHL1 from the membrane might
increase the degradation of α-synuclein, effectively reducing levels
of this aggregation-prone protein and alleviating neuronal stress.
As it will be discussed later, α-synuclein can be degraded by the
proteasome as well as through autophagy. Each type of degrada-
tion rests on Ub-dependent processes that are controlled by DUBs
such as UCHL1 and USP9X (see below). Consequently, targeting
the stability of this disease-linked protein for therapy will require
the consideration of various regulatory processes.
Lastly, in 2013 three siblings from a Turkish family were dis-
covered with a recessive, missense mutation in the Ub-binding
domain of UCHL1 (mutation E7A), which leads to markedly
reduced catalytic activity of this DUB in vitro. Patients from this
family show an early-onset progressive neurodegenerative syn-
drome that includes cerebellar ataxia, spasticity, blindness, and
nystagmus (Bilguvar et al., 2013). These symptoms are different
from those of PD patients, including the ones who carry the I93M
mutation. Such phenotypic variability could be due to different
effects of the E7A and I93M mutations on the activity and inter-
actions of UCHL1, and might be compounded by other genetic
differences between the families.
As we near the end of this section, it is important to note
that mutations in two different DUBs, USP14 and UCHL1, which
function at least by maintaining mono-Ub, cause problems at
the NMJ and neurological defects in mice. Does this mean that
they share duties at the molecular, cellular, and tissue level?
These DUBs are linked through mono-Ub: Uchl1 transcription
is upregulated in axJ mice and, vice versa, Usp14 transcription
is increased in Uchl1-deficient mice (Walters et al., 2008), sug-
gesting a molecular circuitry that controls the expression of these
genes in response to depleted mono-Ub. However, this upregula-
tion at the transcription level does not lead to suppression of the
phenotype, or restitution of mono-Ub levels. Neurological symp-
toms differ among Uchl1- and Usp14-deficient mice, which could
be due to differences in genetic background. As discussed above,
genetic background can have a profound effect on symptoms
and progression of ataxia in Usp14-mutant mice (Marshall et al.,
2013). Another reason why mutations in USP14 and UCHL1
lead to different phenotypes could stem from partially non-
redundant functions. Perhaps there are specific cellular processes
(or substrates), populations of neurons (or glia), or stages of
development for which one DUB is more critical than the other.
While USP14 and UCHL1 have similar effects on the levels of
mono-Ub available in neurons, they likely also play divergent
roles in other aspects of neuronal homeostasis that remain to be
elucidated.
USP7
Amember of the USP sub-family of DUBs, USP7 is also known as
HAUSP. It has gained attention because it is viewed as a potential
therapeutic target for malignancies. Based on numerous studies,
USP7 functions closely with the UPP, where it opposes the pro-
teasomal degradation of various substrates, including the E3 Ub
ligase murine double mutant 2 (mdm2) and its substrate, p53,
a tumor suppressor that causes cell cycle arrest and apoptosis
(Clague et al., 2013). USP7 deubiquitinates both mdm2 (which
enhances p53 degradation) and p53 (which inhibits p53 degrada-
tion) (Li et al., 2002, 2004). It is the interplay of p53 andUSP7 that
may be critical for the nervous system. Through a brain-restricted
knockout strategy for Usp7 in mice, it was shown that this DUB
is essential: mice lacking USP7 in the brain die soon after birth
and have anomalous brain development, attributed in part to p53
protein stabilization as a result of increasedmdm2 turnover in the
absence of USP7 (Kon et al., 2011). p53-independent mechanisms
may also be involved in neonatal lethality, because inactivation of
p53 through a knockout strategy fails to fully rescue lethality in
the absence of USP7 (Kon et al., 2011).
Another potential role for USP7 in the nervous system is the
regulation of the repressor element 1-silencing transcription fac-
tor (REST), which inhibits neural cell differentiation. Knockdown
of USP7 in neuronal progenitor cells leads to a decrease in the lev-
els of REST protein. USP7 and REST co-immunoprecipitate, and
USP7 knockdown results in higher levels of poly-Ub REST, sug-
gesting that USP7 controls REST by deubiquitinating it (Huang
et al., 2011). During differentiation, REST is targeted for protea-
somal degradation by multiple E3 ligases. The levels of one such
ligase, ß-TrCP, increase during neuronal differentiation, when
levels of USP7 and REST are lower. When both USP7 and ß-TrCP
are knocked down, an intermediate level of ubiquitinated REST
is observed compared to its levels in cells where only one pro-
tein is targeted (Huang et al., 2011). According to these results,
ß-TrCP and USP7 counterbalance each other in regulating the
stability of REST. This interaction between USP7 and ß-TrCP is
reminiscent of the USP7/mdm2 exchange with respect to p53. It
is presently unclear whether p53-independent anomalies in brain
development as a result of Usp7 knockout are due to perturba-
tion in REST signaling. Collectively, these studies suggest at least
two major pathways that can be regulated by USP7 in the nervous
system: neuronal differentiation and cell viability.
USP7 may also regulate other processes in the brain, includ-
ing in some neurodegenerative diseases. USP7 interacts with the
gene transcription protein ataxin-1 (Hong et al., 2002), muta-
tions in which cause the age-related neurodegenerative disease
Spinocerebellar Ataxia Type 1 (Williams and Paulson, 2008). The
physiological implications of this interaction are uncertain, but
suggest the possibility of USP7 roles in stages following ner-
vous system development. Lastly, recent studies indicated that
the above-mentioned transcription factor, REST, is positively
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involved in normal ageing, and its loss may be implicated in AD
and mild cognitive impairment (Lu et al., 2014). Considering the
role of USP7 in REST turnover during development, one can
extrapolate that this DUB may be neuroprotective in the ageing
brain by suppressing REST degradation.
USP9X
Another member of the USP sub-family of DUBs implicated in
the nervous system is USP9X. TheDrosophila ortholog of USP9X,
Faf, has been linked to the development of fly eyes and the NMJ
(Fischer-Vize et al., 1992; Diantonio et al., 2001). Faf overex-
pression in Drosophila results in NMJ overgrowth, including an
increase in synaptic span and number of synaptic boutons. Faf
genetically interacts with the E3 ligase Highwire (Hiw), because
loss of function in Hiw results in a phenotype similar to Faf
overexpression (Diantonio et al., 2001). These findings implicate
yet another E3 ligase/DUB pair balancing each other’s func-
tions, although the molecular events downstream of Faf and Hiw
remain to be uncovered.
In fly eyes, Faf prevents over-neuralization during develop-
ment. Fruit flies lacking this DUB or expressing a version that
is catalytically inactive have supernumerary photoreceptors due
to aberrant differentiation of cells that normally acquire non-
neural fates (Fischer-Vize et al., 1992; Huang et al., 1995). The
fate of these cells is specified through Notch-Delta signaling.
Faf genetically interacts with Liquid facets (Lqf), an ortholog of
mammalian epsins involved in endocytosis (Cadavid et al., 2000;
Chen et al., 2002). Lqf is important for Delta internalization
during Notch signaling and thus is a critical component of cell
fate specification. In Drosophila, decreasing Lqf levels enhances
the supernumerary photoreceptor phenotype of Faf mutants,
while increasing Lqf levels renders Faf unnecessary (Cadavid
et al., 2000; Chen et al., 2002). Ubiquitination of Lqf is stabi-
lized in Faf-less eyes, Faf and Lqf co-immunoprecipitate, and
Lqf protein levels are lower in Faf-null mutants (Chen et al.,
2002). These findings lead to the conclusion that Faf regulates
the ubiquitination status and stability of Lqf: in the absence of
Faf, ubiquitinated Lqf could be targeted for proteasomal degra-
dation. It is possible that Lqf ubiquitination also modulates its
activity. The ability of human epsins to interact with partners
can be regulated by mono-ubiquitination (Nijman et al., 2005;
Yi and Ehlers, 2007). Consequently, Faf-dependent deubiquitina-
tion of Lqf may control both its function and stability. The human
version of Faf, USP9X, also interacts with the Lqf ortholog, epsin-
1, and co-localizes with it at the synapse (Chen et al., 2003).
Since RNAi against USP9X stabilizes ubiquitinated epsin-1 in
cultured cells (Chen et al., 2003), we can infer an evolution-
arily conserved role for USP9X in regulating epsin-1 through
deubiquitination.
USP9X has been implicated in two neurodegenerative dis-
orders: PD and Diffuse Lewy Body Disease (DLBD). USP9X
expression is altered in a mouse model of PD (Zhang et al.,
2010), and a portion of USP9X localizes to Lewy Bodies in
PD and DLBD (Rott et al., 2011). Supporting the possibility
of a role for USP9X in disease, studies have linked this DUB
to the stability of α-synuclein, which has been implicated in
the etiology of both PD and DLBD. USP9X is reported to
regulate the cellular turnover of α-synuclein by deubiquitinat-
ing it. RNAi targeting USP9X leads to higher levels of mono-
ubiquitinated α-synuclein in cultured cells and these two proteins
co-immunoprecipitate from cultured cells and rat brain lysates.
Higher levels of mono-ubiquitinated α-synuclein are not well
tolerated by cells (Rott et al., 2011), indicating that USP9X
activity can protect against toxicity from this protein. By deubiq-
uitinating α-synuclein, USP9X seems to specify the degradative
pathway through which this disease protein is disposed: UPP or
autophagy. Unlike other proteins, α-synuclein reportedly only
requires mono-ubiquitination to be degraded by the protea-
some. However, upon deubiquitination by USP9X, α-synuclein
is removed through autophagy (Rott et al., 2011). Perhaps this
information on USP9X and α-synuclein can be used for ther-
apeutics for PD and DLBD. Activators of USP9X are expected
to reduce levels of mono-ubiquitinated α-synuclein—which is
toxic to cells—and to increase its degradation through autophagy,
resulting in a neuroprotective effect.
As mentioned above, membrane-bound, farnesylated UCHL1
can also regulate α-synuclein in cell culture by protecting it from
lysosomal degradation through a mechanism that remains to
be elucidated (Liu et al., 2009). It is tempting to speculate that
UCHL1 prevents the lysosomal degradation of α-synuclein by
directly deubiquitinating it, but this model would not neces-
sarily fit with the data summarized above on USP9X and the
degradation of this disease protein. Potentially, UCHL1 regu-
lates α-synuclein indirectly by controlling other proteins that
dictate its turnover, including perhaps USP9X. Ultimately, ther-
apeutic approaches based on the role of USP9X or UCHL1 on
α-synuclein need to consider how these DUBs might affect each
other’s regulatory effect on this aggregation-prone protein.
Ataxin-3
Ataxin-3 is a member of the MJD sub-family of DUBs. It first
received attention because it is the disease protein in the neurode-
generative disorder Spinocerebellar Ataxia Type 3 (SCA3), also
known as Machado-Joseph Disease. SCA3 is an age-related dis-
ease that belongs to the family of triplet repeat disorders, more
specifically the polyglutamine repeat-related diseases that include
Huntington’s, Spinobulbar Muscular Atrophy, Dentatorubral-
Pallidoluysian Atrophy and five more SCAs (SCA1, 2, 6, 7,
and 17) (Todi et al., 2007). SCA3, which is believed to be
the most common dominantly inherited ataxia in the world,
is a progressive ataxia accompanied by dystonia, dysarthria,
spasticity, rigidity, ophthalmoparesis, dysphagia, and neuropa-
thy. Pathology includes degeneration of cerebellar pathways and
nuclei, pontine and dentate nuclei, substantia nigra, globus pal-
lidus, cranial motor nerve nuclei, and anterior horn cells. SCA3
is caused by a CAG repeat expansion in the gene ATXN3,
which encodes the DUB ataxin-3 (Costa Mdo and Paulson,
2012).
Based on in vitro biochemistry, cell-based studies and in vivo
work in mice, C. elegans and Drosophila, ataxin-3 seems to func-
tion in the UPP (Matos et al., 2011; Costa Mdo and Paulson,
2012). Under some circumstances, ataxin-3 may enhance the
degradation of some proteasome substrates (e.g., in Endoplasmic
Reticulum (ER)-Associated Degradation, Wang et al., 2006, and
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in relation with the Ub ligase CHIP, Scaglione et al., 2011), while
under other conditions it may decelerate proteasomal degrada-
tion of other proteins (Zhong and Pittman, 2006). Since ataxin-3
interacts with several E3 Ub ligases (CHIP, E4B, Hrd1, Parkin)
and with the proteasome-associated proteins hHR23A, hHR23B,
and VCP/p97 (Costa Mdo and Paulson, 2012), this DUB may
regulate the fate of numerous UPP substrates. The precise out-
come of ataxin-3 function—increased or decreased stability of
proteins—most likely depends on the protein partners with which
it interacts.
Through a series of biochemical assays, it was shown that
the E3 Ub ligase CHIP and its E2 partner Ubch5C attach long
poly-Ub chains onto model substrates. Ataxin-3 cooperates with
CHIP/Ubch5C to restrict or edit the length of these poly-Ub
species. This collaboration serves to enhance, rather than pre-
vent, proteasomal degradation of CHIP substrates such as iNOS
(Scaglione et al., 2011), probably because very long poly-Ub can
hinder proteasomal activity (Kim et al., 2007, 2009). Thus, in con-
trast to what was described above for USP7 and mdm2, which
can oppose each other’s activities, ataxin-3 and CHIP appear
to work together to enhance the turnover of at least some pro-
teins. Such collaborative interactions between ligases and DUBs
could be common, because a proteomic study of DUBs identi-
fied numerous E3 Ub ligases co-precipitating with these proteases
(Sowa et al., 2009).
There is also evidence that ataxin-3 can suppress the degra-
dation of some UPP substrates in cells. Work conducted on ER-
Associated Degradation indicates that this DUB deubiquitinates
some misfolded proteins synthesized in the ER, thus prevent-
ing their proteasomal degradation. Ataxin-3 appears to perform
this function in relation with the proteasome-associated protein
VCP/p97 (Zhong and Pittman, 2006), although it has not been
ruled out that ataxin-3 may also directly oppose the function of
ER ligases such as Hrd1 or AMFR.
Three different knockout mouse lines for atxn3 are viable and
appear to live normal lives, indicating that atxn3 is a non-essential
gene (Schmitt et al., 2007; Reina et al., 2010; Switonski et al.,
2011). However, this DUB might be required under certain phys-
iological conditions. For example, mouse embryonic fibroblasts
that lack ataxin-3 fair poorly during heat shock (Reina et al., 2010,
2012). Also, exogenous ataxin-3 suppresses toxicity from poly-
glutamine proteins inDrosophila (Warrick et al., 2005; Tsou et al.,
2013). Whether ataxin-3 has a protective role in vivo in mice is
less clear. In one study, evidence was presented that wild type
ataxin-3 suppresses pathology from its disease-causing version in
mouse models of SCA3 (Cemal et al., 2002). But, in a recent pub-
lication lack of ataxin-3 did not seem to enhance pathology in
a Huntington’s Disease mouse model (Zeng et al., 2013). As this
latter study did not test whether higher levels of ataxin-3 had a
protective effect, or whether catalytically inactive ataxin-3 wors-
ened the HD phenotype, it remains to be clarified whether this
DUB has a neuroprotective effect in mammals.
The molecular mechanisms that lead to polyglutamine-
dependent neurodegeneration in SCA3 are uncertain. Based on
in vitro studies, K48- and K63-linked poly-Ub binding and cleav-
ing capabilities of ataxin-3 are not affected by expansions in
the polyglutamine repeat (Burnett et al., 2003; Winborn et al.,
2008; Todi et al., 2009), although its ability to cleave K27- and
K29-linked poly-Ub is enhanced in the disease-causing version
(Durcan et al., 2011). In cells, polyglutamine-expanded ataxin-3
is less efficient at reducing levels of ubiquitinated species, sug-
gesting that some of its cellular roles are affected by expansion
(Winborn et al., 2008). Supporting the notion that polyglutamine
expansion alters ataxin-3 function, a disease-causing version of
this protease targets the E3 Ub ligase parkin for degradation
through autophagy, unlike wild type ataxin-3 (Durcan et al.,
2011). Based on studies from other polyglutamine proteins such
as ataxin-1 (Lam et al., 2006), polyglutamine repeat expansion
may lead to both a partial loss-of- and a toxic gain-of-function for
ataxin-3, although this remains to be elucidated. Since ataxin-3
appears to be non-essential in mice, perhaps one effective ther-
apeutic route for SCA3 is to get rid of the protein, potentially
without the need to discriminate between normal and pathogenic
forms.
THE USE OF DUBs FOR THERAPEUTIC PURPOSES
The UPP has attracted particular attention from a therapeutic
point of view because of its critical role in protein quality con-
trol and, consequently, in regulating numerous cellular pathways.
Different components of the UPP have been targeted for therapy,
most commonly the proteasome itself, although not directly for
neurological diseases. Therapies focusing on the proteasome have
been developed and have shown promise in the clinic. Bortezomib
(PS-341/Velcade®), which inhibits the activity of the 20S compo-
nent, is a treatment option for multiple myeloma and mantle cell
lymphoma (Clague et al., 2013). Another inhibitor, carfilzomib
(PR-171/Kyprolis®), was generated to treat patients desensitized
to bortezomib. Although both of these inhibitors show prefer-
ence for killing cancer cells, inhibiting the proteasome itself is
largely nonspecific and leads to various undesirable side effects
(Colland, 2010; Mujtaba and Dou, 2011). Focusing on more spe-
cific steps and components upstream of the proteasome could
provide desired therapeutic effects without perturbing general
proteostasis. This is where DUBs might be particularly useful.
Structural work has revealed significant differences in the catalytic
areas of DUBs (Clague et al., 2013) that could be utilized to design
DUB-specific inhibitors. High-throughput screens have identi-
fied small molecule inhibitors for USP7 and UCHL1 (Colland,
2010; Todi and Das, 2012), although the efficacy and overall effect
of these inhibitors in intact animals, particularly in the nervous
system, is not clear.
One DUB that has been targeted therapeutically for the ner-
vous system is USP14. As discussed earlier, this DUB associates
reversibly with the proteasome and is proposed to be important
in maintaining a pool of mono-Ub for utilization. USP14 may
also function by rescuing certain proteins destined for degrada-
tion by deubiquitinating them at the proteasome. Cells that do
not express USP14 have enhanced clearance of several disease-
related proteins, including tau (related to AD), TDP-43 (AD and
Amyotrophic Lateral Sclerosis), and ataxin-3 (SCA3, discussed
above) (Lee et al., 2010a). This finding suggests that inhibiting the
catalytic activity of USP14 may have therapeutic benefits. It is not
clear what cellular conditions or substrate particularities dictate
the ability of USP14 to rescue some substrates from degradation.
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A screen was conducted to identify inhibitors of USP14,
and one particularly promising compound was isolated, 1-
[1-(4-fluorophenyl)-2,5-dimethylpropyl-3-yl]-2-pyrrolidin-1-
ylethanone (abbreviated as IU1), with remarkable specificity
against the catalytic activity of USP14 (Lee et al., 2010a).
Treatment with IU1 enhances the clearance of disease-linked pro-
teins in cultured cells in a manner that is proteasome dependent
(Lee et al., 2010a). A series of in vitro and cell-based experiments
indicated that trimming of poly-Ub chains by USP14 has an
antagonistic effect on protein degradation by the proteasome:
proteasomes incubated with USP14 show decreased degradation
of a model ubiquitinated substrate compared to inactive USP14,
which does not inhibit proteasomal degradation (Lee et al.,
2010a). By inhibiting the deubiquitinating activity of USP14,
IU1 would presumably prevent the rescue of some ubiquitinated
neurotoxic proteins at the proteasome (such as tau and ataxin-3),
leading to their degradation. It remains to be determined if IU1
can prevent neurodegeneration in vivo, particularly in light of
more recent work, which found that overall levels of ataxin-3
and tau were not different in USP14-deficient mice (Jin et al.,
2012). These potential discrepancies in findings from cultured
cells and intact animals could result from different handling
of ataxin-3 and tau in vitro vs. in vivo. Acute inactivation of
USP14 could increase the degradation of some disease proteins
by the proteasome without perturbing Ub homeostasis, whereas
chronic inactivation could cause an overall disturbance in
mono-Ub availability that leads to compensatory mechanisms
of protein turnover (such as lysosomal-dependent degradation).
Additonally, inactivation or depletion of USP14 may not have
beneficial effects in all neurodegenerative diseases. USP14 can
reduce aggregates formed by mutant huntingtin (which causes
Huntington’s Disease) and can suppress cellular degeneration
caused by this protein (Hyrskyluoto et al., 2014). The molecular
mechanism through which USP14 has this neuroprotective
effect in cells is not known, but it might involve: (1) mono-Ub
availability for proper UPP function, (2) the deubiquitination
of huntingtin aggregates, which are heavily ubiquitinated, for
better recognition, access and degradation by the proteasome, as
well as (3) changes in ER-Associated Degradation (Hyrskyluoto
et al., 2014). Altogether, these findings stress the importance
of a deep understanding of the UPP before targeting specific
components for blanket therapeutics in neurodegenerative
diseases.
Other studies have hinted at potential molecules that could
be used to regulate DUB activities in the nervous system. A
recent report that investigated the mechanism through which
metal complexes inhibit proteasome function for cancer ther-
apy found that copper pyrithione (CuPT) acts at two distinct
steps: (1) by inhibiting the activity of the 20S component, and
(2) by inhibiting USP14 and UCHL5 (Liu et al., 2014). CuPT
might be a promising cancer therapeutic by inhibiting UPP and
causing cellular death in malignant cells, although its utility
in neurodegenerative diseases is doubtful. Inhibiting neuronal
UPP would be detrimental to the nervous system and would
exacerbate pathology. Still, CuPT might be an important experi-
mental reagent to understand the function of USP14 and UCHL5
in the nervous system, especially if this complex can be mod-
ified so that its inhibitory roles on the 20S and USP14 and
FIGURE 4 | Summary of DUBs involved in various steps of the UPP.
Summary of the various steps of substrate ubiquitination and degradation
during which specific DUBs involved in the UPP are reported to function.
UCHL1 maintains a pool of mono-Ub for conjugation by removing additional
amino acids present in newly translated Ub, or by processing accidental thiol
or amine modifications formed during Ub reactions. Once a substrate has
been ubiquitinated, DUBs such as USP7, USP9X and under some
circumstances, ataxin-3 can deubiquitinate and rescue it from proteasomal
degradation. Ataxin-3 has also been reported to enhance the degradation of a
few substrates by editing poly-Ub chains for better recognition by and access
to the proteasome. Once at the proteasome, premature deubiquitination
of substrates by USP14 can prevent degradation. If a proteasome-bound
substrate has been committed to degradation and is being unfolded,
deubiquitination by PSMD14, UCHL5, and USP14 recycles Ub.
Frontiers in Molecular Neuroscience www.frontiersin.org August 2014 | Volume 7 | Article 72 | 11
Ristic et al. DUBs and the UPP in the nervous system
UCHL5 are dissociated. A molecule with such properties in fact
exists: b-AP15, which inhibits the DUB activity of USP14 and
UCHL5 (D’Arcy et al., 2011). To the best of our knowledge, nei-
ther compound has reportedly been utilized to investigate the
nervous system.
CONCLUSIONS
Understanding the functions of enzymes important for the
removal of Ub from substrates targeted for UPP-dependent
degradation provides a deeper appreciation of a basic cellular
process essential to all eukaryotic cells. We hope to have made a
convincing case that DUBs that function in conjunction with the
UPP play critical roles in nervous system development, function,
and disease.
The job of the UPP is to identify proteins that need to be
degraded and selectively send them to be destroyed by the pro-
teasome through the utilization of an identifier, in this case,
ubiquitination. DUBs are among the various checkpoints that
ensure the ubiquitination of correct substrates. Some such pro-
teases, like ataxin-3, can function by editing the type of chain
attached to a substrate in order to enhance the proteasomal degra-
dation of a specific protein. Others, exemplified by USP7 and
USP9X, can oppose the function of specific E3 Ub ligases, leading
to the stabilization of some proteasomal substrates. DUBs such
as UCHL1, UCHL5, and PSMD14 seem critical for mono-Ub
homeostasis; others, like USP14, control the UPP through multi-
ple, seemingly contradictory, activities: by recycling Ub for reuse,
by increasing proteasome function, and sometimes by rescuing
specific substrates from degradation (Figure 4).
As there are nearly 95 genes encoding DUBs in humans, one
would think that there would be redundancy built into the func-
tions of this family of proteases. However, studies in various
animal models indicate that redundancy is not common among
DUBs (Clague et al., 2013). Mutations or knockouts of different
DUBs lead to distinct developmental anomalies or neurologi-
cal disorders, supporting the idea that while some DUBs share
duties, they also have roles in pathways, cells, tissues, organs, and
stages of development that cannot be fully compensated by other
members of their family.
While we have learned a tremendous amount about the UPP
and the role of DUBs in it, much remains to be uncovered, par-
ticularly in relation to the nervous system. Each time a door is
opened by new research, a spiraling corridor is revealed withmore
possibilities to consider and opportunities to explore. Details
on UPP-related DUBs in specific neuronal circuits are limited.
We lack an expression and localization atlas of DUBs during
development and in adults, during increased periods of activity
and in resting times, in different areas of the brain and spinal
cord, in different types of neuronal and glial cells and in dis-
tinct sub-cellular compartments. Such information is critical if
we are to understand why the perturbation of DUBs that are
supposed to have somewhat related functions has different out-
comes in intact organisms. Rewards from the continued study of
DUBs and UPP in the nervous system are expected to be great,
both in terms of comprehending basic mechanisms of neuronal
physiology, and in understanding and treating diseases of the
nervous system.
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